ONCOCROSS

  • Company

    • Mission

    • About Us

    • History

    • Leadership

    • Scientific Advisory Board

  • Business Areas

    • Neo Omics

    • DBB

    • Early Cancer Detection & Monitoring

    • Collaboration

  • Technology Platform

    • RAPTOR AI® VERSION 2.0

    • ONCOfind AI ®

  • Pipeline

  • News/IR

    • Notice

    • Press Releases

    • IR Materials

    • Knowledge Hub

    • Latest Cancer Information

    • Disclosure Information

    • Stock Information

  • OncoMaster

CONTACT US
  • KR
  • EN
  • Company

    • Mission

    • About Us

    • History

    • Leadership

    • Scientific Advisory Board

  • Business Areas

    • Neo Omics

    • DBB

    • Early Cancer Detection & Monitoring

    • Collaboration

  • Technology Platform

    • RAPTOR AI® VERSION 2.0

    • ONCOfind AI ®

  • Pipeline

  • News/IR

    • Notice

    • Press Releases

    • IR Materials

    • Knowledge Hub

    • Latest Cancer Information

    • Disclosure Information

    • Stock Information

  • OncoMaster

  • KR
  • EN
CONTACT US
  • Main
  • News/IR
  • Press Releases

Press Releases

181 Posts
  • 이코노미스트

    [단독] 대웅제약이 투자한 ‘온코크로스’, 2년 만에 IPO 재도전

    06-19-2023
  • 더벨

    R&D에 파트너 끌어들인 JW그룹, 자체역량 확보했다

    05-11-2023
  • ClinicalTrialsArena

    Oncocross completes Phase I sarcopenia trial in Australia

    05-11-2023
  • CEO SCORE DAILY

    동화약품, EZH1/2 저해제 개발 박차…항암제 사업 강화

    05-10-2023
  • BUSINESSWIRE

    Oncocross Completes Phase I Global Clinical Trial of OC514, Treatment for Sarcopenia

    05-10-2023
  • 글로벌이코노믹

    [창간특집] "AI 활용 신약개발, 우리도 있다"…국내외 '러브콜' 받는 온코크로스

    05-09-2023
  • 포인트데일

    "제약·바이오 화두 'AI 신약'… 투자 리스크 커 '오픈 이노' 참여 선호"

    05-09-2023
  • 뉴데일리

    제약사, AI 바이오텍 온코크로스와 잇따라 맞손... 적응증 확대 시도

    03-03-2023
  • 스마트타임스

    Boryung Expands AI Venture Oncocross and Canav Adaptations

    02-24-2023
  • 머니투데이

    보령-온코크로스, AI 이용해 고혈압 치료제 '카나브' 적응증 확대

    02-24-2023
  • 바이오스펙테이터

    보령-온코크로스, ‘카나브’ 적응증 확대 “공동연구 계약”

    02-24-2023
  • 서울경제

    "AI·신약개발 전문성 합쳐야 후보물질 발굴 시간도 단축"

    01-04-2023
  • 1
  • 2
  • 3
  • 4
  • 5
  • ›
  • »

Please enter a prompt

ONCOCROSS
CEO
Yi Rang KIM / Jihoon KANG
Address
Room 905, 7 Beobwon-ro 11-gil, Songpa-gu, Seoul, Korea (Munjeong-dong, Munjeong Hyundai Knowledge Industry Center 1-2)
Tel
02-717-9967
Fax
02-867-9968
Email
oncocross@oncocross.com
Terms & Conditions Privacy Policy Cookie Policy
ⓒ ONCOCROSS CO., LTD. All Rights Reserved.